超越二线治疗:晚期肝细胞癌系统治疗的战略序贯
本综述整合II/III期试验及真实世界研究(超4000例患者)证据,阐述晚期肝细胞癌一线免疫联合治疗后如何序贯治疗;TKI类中位总生存约10-11个月,肝功能保留决定治疗资格及进展后生存,并提出CUSE框架支持多学科决策。
要点
- 免疫联合治疗后TKI序贯可行,中位总生存约10-11个月
- 肝功能保留始终决定治疗资格与进展后生存
- CUSE框架将序贯治疗视为整合毒性、可行性与患者价值观的适应性过程
核心结论
- 晚期肝细胞癌系统治疗已从线性序贯演变为由疗效、肝功能与可及性塑造的多维过程,序贯策略超越二线治疗范畴。
研究设计与样本
- 综述整合II期和III期试验及真实世界研究证据,涵盖全球不同地区超过4000例患者。
主要发现
- 免疫联合治疗后,酪氨酸激酶抑制剂仍为有活性且可行的选择,中位总生存约10-11个月。
- 肝功能保留一致地决定治疗资格和进展后生存。
- 引入巴塞罗那临床肝癌分期「治疗应答时」概念,细化对主要缓解或转化患者的分类并与当代治疗动态对齐。
- CUSE框架涵盖复杂性、不确定性、主观性和情感,将序贯治疗重构为整合毒性、可行性及患者价值观的适应性、以患者为中心的过程。
- 完全或主要缓解后的转化治疗和「停药」策略代表新兴前沿,强调肝细胞癌序贯已超越二线治疗。
关键数值与推荐
- 免疫联合治疗后TKI序贯的中位总生存约10-11个月。
临床怎么用
- 临床决策应整合疗效、肝功能、毒性、可行性和患者价值观进行序贯规划。
- 保留肝功能以维持治疗资格并优化全程管理结局。
- 采用CUSE等多维框架支持多学科推理和治疗序贯的概念一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic therapy for advanced HCC has evolved from a linear, stepwise algorithm into a multidimensional and truly polyhedral process shaped by treatment response, liver function, and access to therapy. This review integrates evidence from phase II and III trials and real-world studies, including more than 4000 patients across different global regions, to outline how sequencing beyond first-line immunotherapy is redefining clinical practice. After immune-based combinations, tyrosine kinase inhibitors remain active and feasible options, achieving a median overall survival of ~10-11 months, while preservation of liver function consistently determines treatment eligibility and postprogression survival. Incorporation of the Barcelona Clinic Liver Cancer concept "upon response" refines classification for patients achieving major responses or conversion and aligns staging with contemporary treatment dynamics. The CUSE framework-encompassing complexity, uncertainty, subjectivity, and emotion-reframes sequencing as an adaptive, patient-centered, and multifaceted process that integrates toxicity, feasibility, and patient values alongside efficacy. By structuring diverse clinical inputs into a unified interpretive model, CUSE supports multidisciplinary reasoning and enhances conceptual coherence in treatment sequencing. Conversion therapy and "drug-off" strategies following complete or major responses represent emerging frontiers, emphasizing that sequencing in HCC now extends beyond second-line therapy. Additionally, preserving hepatic function and applying polyhedral, data-informed decision frameworks are key to sustaining eligibility and optimizing outcomes across the continuum of care.
引用
- Fortuny M, Chan LL, da Fonseca LG, et al. Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma. Hepatology. 2026. PMID: 42289095. doi:10.1097/HEP.0000000000001767
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。